Assenagon Asset Management S.A. Makes New Investment in Xenon Pharmaceuticals Inc. $XENE

Assenagon Asset Management S.A. bought a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 119,186 shares of the biopharmaceutical company’s stock, valued at approximately $5,342,000.

A number of other hedge funds have also recently modified their holdings of the business. Arizona State Retirement System increased its position in shares of Xenon Pharmaceuticals by 1.8% during the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock worth $774,000 after acquiring an additional 334 shares during the period. Quarry LP raised its stake in shares of Xenon Pharmaceuticals by 25.0% in the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 500 shares in the last quarter. State of Wyoming boosted its holdings in Xenon Pharmaceuticals by 112.8% in the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 610 shares during the period. Danske Bank A S acquired a new position in Xenon Pharmaceuticals during the 3rd quarter worth $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in Xenon Pharmaceuticals during the 3rd quarter worth $39,000. Institutional investors own 95.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on XENE shares. Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. JPMorgan Chase & Co. boosted their price objective on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Wolfe Research initiated coverage on shares of Xenon Pharmaceuticals in a research note on Monday, February 23rd. They set an “outperform” rating and a $60.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and issued a $90.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, HC Wainwright lifted their price target on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $71.88.

Xenon Pharmaceuticals Price Performance

Xenon Pharmaceuticals stock opened at $54.48 on Friday. The stock has a market cap of $4.53 billion, a PE ratio of -12.50 and a beta of 0.91. The stock’s fifty day moving average is $46.43 and its two-hundred day moving average is $43.07. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period last year, the business earned ($0.84) earnings per share. On average, research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Ian Mortimer sold 7,308 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $403,620.84. Following the completion of the sale, the chief executive officer owned 19,923 shares in the company, valued at approximately $1,100,347.29. The trade was a 26.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher John Kenney sold 1,410 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $77,874.30. Following the completion of the transaction, the insider owned 7,069 shares of the company’s stock, valued at approximately $390,420.87. The trade was a 16.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 336,707 shares of company stock valued at $19,622,565. 4.07% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.